Drug Profile


Alternative Names: ATM-AVI; Aztreonam-avibactam

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Amides; Antibacterials; Heterocyclic bicyclo compounds; Monobactams; Small molecules; Sulfates
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Intra-abdominal infections
  • Phase I Gram-negative infections

Most Recent Events

  • 24 Aug 2016 AstraZeneca plans to sell the commercialisation and development rights to late-stage small molecule antibiotics to Pfizer
  • 01 May 2016 Phase-II clinical trials in Intra-abdominal infections in Germany, Spain (IV) (NCT02655419)
  • 29 Jan 2016 Allergan and AstraZeneca enter into a global agreement to develop and commercialise avibactum/aztreonam
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top